← SEC 公告列表 | APRE SEC 公告 | Aprea Therapeutics, Inc.（APRE）

重大事件 即時報告 8-K 2026-07-23

Aprea Therapeutics 獲納斯達克延長180日合規期至2027年1月 股價仍低於1美元面臨除牌風險

於 SEC 網站開啟原文

AI 繁中摘要

📄 申報類型：8-K 🗓️ 報告日期：2026年7月23日 🏢 公司：Aprea Therapeutics, Inc.（納斯達克代碼：APRE） Aprea Therapeutics 於7月23日收到納斯達克上市資格部門的通知，表示公司尚未符合每股最低 bid price 1美元的持續上市要求（Nasdaq Listing Rule 5550(a)(2)）。然而，納斯達克裁定公司符合資格，可再多獲得180個曆日（即第二個合規期），直至2027年1月19日為止，以重新達到最低買入價要求。 此前，公司已於2026年1月23日收到首個合規期通知，原定於2026年7月22日屆滿。現在納斯達克額外給予約半年時間。 若在第二合規期內的任何時間，公司普通股收盤 bid price 連續至少10個交易日達到或超過1美元，納斯達克將發出書面確認，表示公司已恢復合規。若截至2027年1月19日仍未能證明符合規定，納斯達克則會發出書面通知，啟動除牌程序。屆時，公司有權向納斯達克聽證小組提出上訴。 ⚠️ 對投資者的潛在影響：Aprea Therapeutics 面臨除牌風險，股價持續低於1美元可能影響流動性及市場信心。管理層需在未來數月內採取行動（如股份合併或提升股價措施）以維持上市地位。投資者應密切留意股價走勢及公司後續公告。
展開英文正文 
false
 0001781983
 
 
 
 
 
 
 
 0001781983
 
 
 2026-07-23
 2026-07-23
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 iso4217:USD
 
 
 xbrli:shares
 
 
 
 
 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

July 23, 2026

Date of Report (Date of earliest event reported)

 

 

Aprea Therapeutics, Inc.

(Exact name of registrant as specified in its
charter)

 

 

 Delaware
 001-39069
 84-2246769

 (State or other jurisdiction

of incorporation)
 
 (Commission

 File Number)

 
 (IRS Employer

 Identification No.)

  
  
  

 
 3805 Old Easton Road

 Doylestown, PA

 (Address of principal executive offices)

 
  

 18902

 (Zip Code)

  
  
  
  

 
 Registrant's telephone number, including
 area code: (215) 948-4119

  

 (Former name or former address,
if changed since last report): Not applicable 

 

 

Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Securities registered pursuant to Section 12(b) of the
Act:

 

 Title of each class 
  
 Trading Symbol(s) 
  
 
 Name of each exchange on 

 which registered 

 Common stock, par value $0.001 per share
  
 APRE
  
 The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

  

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.

 

On July 23, 2026, Aprea
Therapeutics, Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”)
informing the Company that, while the Company has not yet regained compliance with the $1.00 minimum bid price required for continued
listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”),
Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until January 19, 2027 (the “Second
Compliance Period”), to regain compliance with the Minimum Bid Price Requirement.

 

As previously reported, on
January 23, 2026, the Company received a deficiency notice from Nasdaq informing the Company that its common stock (the “Common
Stock”) had failed to comply with the Minimum Bid Price Requirement and, pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the
Company was initially provided 180 calendar days, or until July 22, 2026, to regain compliance.

 

If at any time during the
Second Compliance Period, the closing bid price of the Common Stock is at least $1.00 per share for a minimum of 10 consecutive business
days, Nasdaq will provide the Company with written confirmation of compliance. If compliance with the Minimum Bid Price Requirement cannot
be demonstrated by January 19, 2027, Nasdaq will provide written notification that the Common Stock will be delisted from Nasdaq.
At that time, the Company may appeal Nasdaq’s determination to a hearings panel.

 

  

  

 

 

SIGNATURES

 

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.

 

 
  
 Aprea Therapeutics, Inc.

 
  
  

 
 Dated: July 23, 2026
 By:
 /s/ Oren Gilad

 
  
 Name:
 Oren Gilad, Ph.D.

 
  
 Title:
 President and Chief Executive Officer